Market closedNon-fractional
Compass Therapeutics/CMPX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
Ticker
CMPX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
32
Website
www.compasstherapeutics.com
CMPX Metrics
BasicAdvanced
$144M
Market cap
-
P/E ratio
-$0.35
EPS
0.73
Beta
-
Dividend rate
Price and volume
Market cap
$144M
Beta
0.73
Financial strength
Current ratio
40.743
Quick ratio
40.137
Long term debt to equity
0.12
Total debt to equity
0.9
Management effectiveness
Return on assets (TTM)
-19.13%
Return on equity (TTM)
-27.35%
Valuation
Price to book
0.92
Price to tangible book (TTM)
0.92
Price to free cash flow (TTM)
-3.216
Growth
Earnings per share change (TTM)
-1.94%
3-year earnings per share growth (CAGR)
-21.67%
What the Analysts think about CMPX
Analyst Ratings
Majority rating from 7 analysts.
CMPX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
-20.15%
Profit margin
0.00%
NaN%
CMPX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.08
-$0.11
-$0.08
-
Expected
-$0.08
-$0.11
-$0.09
-$0.11
-$0.09
Surprise
10.53%
-25.33%
16.84%
-29.11%
-
CMPX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Therapeutics stock?
Compass Therapeutics (CMPX) has a market cap of $144M as of July 27, 2024.
What is the P/E ratio for Compass Therapeutics stock?
The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of July 27, 2024.
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Compass Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.